Navigation Links
Nasal mucosal inhalation of AD vaccine attenuates Aβ1-42-induced cytotoxicity
Date:7/9/2014

Cholinergic inhibitors and N-methyl-D-aspartate receptor antagonists can alleviate the symptoms of Alzheimer's disease, but fail to affect irreversible cognitive dysfunction and effectively scavenge amyloid beta peptide in the brain. Amyloid beta peptide (Aβ) vaccines reduced and eliminated Aβ deposition in an Alzheimer's disease (AD) transgenic mouse model, and significantly improved behavioral and cognitive impairment. Dr. Yunpeng Cao and his team, First Affiliated Hospital of China Medical University, China immunized AD transgenic mouse models with Plp-Adeno-X-CMV-(Aβ3-10)10-CpG via nasal mucosal inhalation. They found that Plp-Adeno-X-CMV-(Aβ3-10)10-CpG vaccine can produce strong T helper 2 humoral immune responses, and avoid Aβ1-42-caused T helper 1 immune responses and Aβ1-42-induced cytotoxicity. Therefore, Plp-Adeno-X-CMV-(Aβ3-10)10-CpG vaccine can be used as a novel type of AD vaccine. These findings were published in Neural Regeneration Research (Vol. 9, No. 8, 2014).


'/>"/>

Contact: Meng Zhao
eic@nrren.org
86-138-049-98773
Neural Regeneration Research
Source:Eurekalert

Page: 1

Related biology news :

1. Intranasal neuropeptide Y may offer therapeutic potential for post-traumatic stress disorder
2. AcelRx Pharmaceuticals Receives First U.S. Patent for Small-Volume Oral Transmucosal Dosage Forms
3. First positive results toward a therapeutic vaccine against brain cancer
4. Researchers shut down a SARS cloaking system; findings could lead to SARS, MERS vaccines
5. UNL team explores new approach to HIV vaccine
6. Ebola vaccine success highlights dilemma of testing on captive chimps to save wild apes
7. New experimental vaccine produces immune response against MERS virus
8. New technique brings us closer to HIV and Hepatitis C vaccines
9. Potential lung cancer vaccine shows renewed promise
10. Researchers have identified a novel immunological mechanism of great importance for vaccine developm
11. Can personalized tumor vaccines improve interleukin-2 treated metastatic melanoma?
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/16/2016)... 2016 Sensory Inc ., a ... for consumer electronics, and VeriTran , a ... industry, today announced a global partnership that will ... authenticate users of mobile banking and mobile payments ... software which requires no specialized biometric scanners, yet ...
(Date:11/14/2016)... Inc. ("xG" or the "Company") (Nasdaq: XGTI, XGTIW), a ... challenging operating environments, announced its results for the third ... conference call to discuss these results on November 15, ... Key Recent Accomplishments The ... Vislink Communication Systems. The purchase is expected to close ...
(Date:6/22/2016)... , June 22, 2016  The American College of Medical ... Show Executive Magazine as one of the fastest-growing trade ... 25-27 at the Bellagio in Las Vegas ... highest percentage of growth in each of the following categories: ... companies and number of attendees. The 2015 ACMG Annual Meeting ...
Breaking Biology News(10 mins):
(Date:12/8/2016)... DIEGO , Dec. 8, 2016  Renova™ ... for congestive heart failure and type 2 diabetes, ... for a novel adeno-associated virus (AAV) vector developed ... , M.D., Ph.D., at Stanford University. The company ... its paracrine gene therapy product pipeline. ...
(Date:12/8/2016)... 8, 2016 Oxford Gene Technology ... SureSeq™ NGS panel range with the launch of the SureSeq ... study of variants in familial hypercholesterolemia (FH). The panel delivers ... on a single small panel and allows customisation by ,mix ... all exons for LDLR , P C ...
(Date:12/8/2016)... (PRWEB) , ... December 08, 2016 , ... This CAST ... approvals for biotech crops. The authors focus on the economic effects in countries that ... approval of new biotech crops and the resultant risk of low level presence (LLP) ...
(Date:12/8/2016)... SEOUL, South Korea , Dec. 8, 2016 /PRNewswire/ ... completed a $21 billion KRW (US $18.9M) Series A ... Management, Kolon Investment, G.N. Tech Venture and SNU Bio ... by Eutilex to 30.5 billion KRW (US $27.7M) since ... will help Eutilex to bolster the development and commercialization ...
Breaking Biology Technology: